Trial to assess feasibility, safety of CAR T-cell therapy for relapsed pediatric central nervous system tumors

관련뉴스

1. Trial to assess CAR T-cell therapy for relapsed, refractory solid tumors A trial underway at Seattle Children’s Hospital will evaluate chimeric antigen receptor T-cell therapy for children and young adults with relapsed or refractory noncentral nervous system EGFR-expressing solid tumors. The EGFR protein often is expressed … (본문 전체 9/24/2018 10:17 PM)...
   
   
2. CAR T-cell therapy ‘quite promising’ for glioblastoma Chimeric antigen receptor T-cell therapy may overcome some of the obstacles associated with systemic therapy for patients with glioblastoma, according to a review published in Neuro-Oncology. Although progress with chimeric antigen receptor (CAR) T-cell … Date : 2018-07-17T14:08:00.000Z Source : https://www.healio.com/hematology-oncology/neuro-oncology/news/online/%7B66c3e2bc-9965-45f7-8d5b-4cf21f380777%7D/car-t-cell-therapy-quite-promising-for-glioblastoma...
   
   
3. Top hematology/oncology stories: Trial to assess CAR T-cell therapy, FDA approves Copiktra Among the top stories in hematology/oncology this week were the announcement of a trial to assess CAR T-cell therapy for relapsed and refractory solid tumors for children and young adults and the FDA approval of Copiktra for leukemia and lymphoma subtypes. (본문 전체 10/5/2018 12:06 AM)...
   
   
4. Trial to assess CAR T-cell therapy for certain lymphomas, leukemias Researchers are launching a first-in-human clinical trial to assess the use of chimeric antigen receptor T-cell therapy targeting the CD4 protein among patients with relapsed and refractory T-cell lymphoma and leukemia. Huda S. Salman, MD, oncologist at … (본문 전체 11/28/2018 3:55 AM)...
   
   
5. CAR T-cell therapy appears cost-effective in pediatric leukemia Tisagenlecleucel appears to be priced in line with its estimated long-term survival benefit among children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia, according to results of a cost-effectiveness analysis published in … (본문 전체 10/9/2018 10:37 PM)...
   
   
6. Checkpoint inhibitors enhance CAR T-cell therapy in relapsed B-cell acute lymphoblastic leukemia SAN DIEGO — Checkpoint inhibitors appeared to safely and effectively improve outcomes with CD19-directed chimeric antigen receptor T-cell therapy among children with relapsed B-cell acute lymphoblastic leukemia, according to a study presented at ASH … (본문 전체 12/2/2018 6:57 AM)...
   
   
7. Gene editing may enhance CAR T-cell therapy for hematologic malignancies Researchers at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis have used gene editing technology known as CRISPR to engineer human T cells to attack certain cancers. Results from studies conducted … Date : 2018-07-17T20:39:00.000Z Source : https://www.healio.com/hematology-oncology/leukemia/news/online/%7B36c82695-07c0-4de6-88a1-db5aba5043cf%7D/gene-editing-may-enhance-car-t-cell-therapy-for-hematologic-malignancies...
   
   
8. CAR T-cell therapy: What you need to know Chimeric antigen receptor T-cell therapy, also known as CAR T-cell therapy, is approved for two indications — relapsed or refractory large B-cell lymphoma and B-cell acute lymphoblastic leukemia — and is currently being investigated for more cancer types. (본문 전체 8/4/2018 8:45 AM)...
   
   
9. Pediatric CAR T-cell therapy guidelines highlight need for interdisciplinary monitoring Children treated with chimeric antigen receptor T-cell therapy experience unique toxicities that require careful monitoring to prevent serious sequalae, according to new management guidelines. An educated interdisciplinary team — including nurses … (본문 전체 8/15/2018 3:17 AM)...
   
   
10. Top oncology stories: UK panel rejects CAR T-cell therapy, comorbidities predict poor leukemia prognosis Among the top stories in hematology/oncology this past week were a report on The National Institute for Health and Care Excellence’s draft guidance that stated that CAR T-cell therapy is too expensive to justify its use in England’s National Health … (본문 전체 9/6/2018 9:11 PM)...
    
    
11. CAR T-cell therapy appears safe for multiple myeloma The chimeric antigen receptor T-cell therapy P-BCMA-101 appeared safe among patients with relapsed/refractory multiple myeloma, according to the agent’s manufacturer. P-BCMA-101 (Poseida Therapeutics) — a stem cell memory chimeric antigen receptor (CAR … (본문 전체 9/6/2018 11:21 PM)...
    
    
12. The Curative Potential of CAR-T Cell Therapy in Mantle Cell Lymphoma Though it is still being tested in clinical trials, CAR-T cell therapy can offer hope for patients with mantle cell lymphoma whose disease relapsed. BY Andre Goy, M.D., M.S. PUBLISHED July 26, 2018 Chimeric antigen receptor (CAR)-T cell therapy is … Date : 2018-07-26T15:40:00.000Z Source : https://www.curetoday.com/cure-tv/the-curative-potential-of-car-t-cell-therapy-in-mantle-cell-lymphoma...
    
    
13. Phase I clinical trial shows safety and tolerability of HIV-specific, ex-vivo expanded T-cell therapy Preliminary results from a phase I clinical trial have demonstrated the safety and tolerability of a cell therapy involving the ex vivo expansion of T cells and their subsequent infusion into HIV-infected individuals previously treated with antiretroviral … (본문 전체 9/24/2018 8:32 PM)...
    
    
14. Role of CAR T-Cell Therapy in Pediatric ALL Continues to Be Refined While clinical trial findings with chimeric antigen receptor (CAR) T-cell therapy have impacted the landscape of pediatric acute lymphoblastic leukemia (ALL), most notably with the 2017 FDA approval of tisagenlecleucel (Kymriah), additional CAR T-cell … (본문 전체 9/14/2018 11:53 AM)...
    
    
15. NHLBI pauses cell therapy trial over concerns about `scientific foundations’ The NHLBI announced it has paused the CONCERT-HF trial testing a cell therapy for patients with HF due to “concerns about the scientific foundations of this trial.” Per a press release from the institute, concerns have been raised about the legitimacy … (본문 전체 10/30/2018 4:43 AM)...
    
    
16. NHLBI pauses cell therapy trial over concerns about ‘scientific foundations’ The NHLBI announced it has paused the CONCERT-HF trial testing a cell therapy for patients with HF due to “concerns about the scientific foundations of this trial.” Per a press release from the institute, concerns have been raised about the legitimacy … (본문 전체 10/31/2018 10:57 PM)...
    
    
17. Cell therapy for knee cartilage damage did not meet primary endpoint in phase 3 trial Histogenics Corporation announced in a press release that the phase 3 clinical trial of its restorative cell therapy NeoCart did not meet its primary endpoint of statistically significant improvement in pain and function 1 year after treatment compared … (본문 전체 9/27/2018 4:12 AM)...
    
    
18. Gilead brings Medicxi’s tiny Gadeta into the cell therapy fold, hunting a way to pick the lock on solid tumors The battleship Gilead has added a small but potentially remarkable biotech tug boat to its fast-growing cell therapy drug fleet. The biopharma powerhouse’s CAR-T company Kite is allying with tiny Gadeta in the Netherlands, inking a deal to collaborate on … Date : 2018-07-19T12:30:00.000Z Source : https://endpts.com/gilead-brings-medicxis-tiny-gadeta-into-the-cell-therapy-fold-hunting-a-way-to-pick-the-lock-on-solid-tumors/...
    
    
19. CAR-T Cell Therapy Combination Shows Promise in Relapsed/Refractory Leukemia Using chimeric antigen receptor (CAR)-T cell therapy plus Imbruvica (ibrutinib), a targeted treatment, could improve outcomes in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to study findings presented during the 2018 … (본문 전체 12/4/2018 11:09 PM)...
    
    
20. UK panel rejects CAR T-cell therapy due to cost An independent body that offers guidance to improve health and social care in England recommended against the use of axicabtagene ciloleucel, one of two chimeric antigen receptor T-cell therapies already approved in the United States and European Union. (본문 전체 8/29/2018 3:32 AM)...